Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 4 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

Pathogenesis-based therapy safe, effective for porokeratosis

18 Jan 2020
4 facts about cholesterol and statin you may not know

Treatment with topical cholesterol/lovastatin is effective and well-tolerated for patients with porokeratosis, results of a recent study have shown.

This highlights the value of a pathogenesis-based therapy that replaces deficient end products and prevents accumulation of potentially toxic precursors, according to the investigators.

A series of five porokeratosis patients (one with disseminated superficial actinic porokeratosis, two with porokeratosis palmaris et plantaris disseminate and two with linear porokeratosis) was included in this study that sought to assess the efficacy of topical cholesterol/lovastatin in different variants of the disease.

Patients were genotyped prior to treatment initiation. Subsequently, they applied topical cholesterol/lovastatin twice daily to a unilaterally defined treatment area for a duration of up to 3 months. The investigators then evaluated the response and photographed the patients at every visit.

MVD and PMVK mutations were present in three and two patients, respectively. Treatment with topical cholesterol/lovastatin, but not cholesterol alone, led to a near complete clearance of disseminated superficial actinic porokeratosis lesions after 4 weeks of therapy and to moderate improvement of porokeratosis palmaris et plantaris disseminate lesions and linear porokeratosis lesions.

No adverse events were reported. The study, however, was limited by its case series design and its small sample size.

“Porokeratosis is associated with mevalonate pathway gene mutations,” the investigators explained, adding that therapeutic options are few and often have limited efficacy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 4 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.